Prostate Cancer - Localized Adenocarcinoma Proton Therapy
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
Prostate Adenocarcinoma
DEVICE: Proton Therapy
BCFFS, To evaluate biochemical failure-free survival (BCFFS), up to 5 years from a initial follow-up
Acute/late toxicity (CTCAE v4.0), Common Terminology Criteria for Adverse Events (CTCAE) V 4.0, up to 5 years from a initial follow-up|Disease specific survival, follow-up, up to 5 years from a initial follow-up|EPIC (Extended Prostate Cancer Index Composite), questionnaire, up to 5 years from a initial follow-up
For Proton therapy with prostate adenocarcinoma patients.

Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks.

Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.